ClinicalTrials.gg
RecruitingNCT05914636AneBioteUpdated Nov 2, 2026

Evaluation of Intestinal Microbiota Implication in Ruptured Intracranial Aneurysm

An observational study in Intracranial Sacciform Aneurysm, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Hospices Civils de Lyon · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Updated Nov 2, 2026Now RecruitingFirst site in France+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 66 studies in Intracranial Aneurysm with a site in France — 19 open to participants now, 26 under way, 1 of them phase 3. Intracranial Aneurysm · France.

Planned enrollment
41st of 43
50 · median 206
Started
2025
with 3 others
Observational
43 of 66
10 open now
Primary completion
2029-06
later than 13 of 25 live
Registered
55th of 66
by date
Lead sponsor
2 of 66
Hospices Civils de Lyon

Among the 66 studies in Intracranial Aneurysm with a site in France, this one is the 41st largest by planned enrollment of the 43 observational ones that give a count, is one of 4 that started in 2025, is one of 43 observational ones, reaches primary completion later than 13 of the 25 other live ones, and was the 55th registered.

Intracranial Aneurysm

419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.

Browse Intracranial Aneurysm studies →

Open to participants now

19 of the 66 studies in Intracranial Aneurysm with a site in France are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Intracranial Aneurysm with a site in France, or all of them as a file.
02

Study summary

The physiopathology of intracranial aneurysm from initiation to ruptured is incompletely understood but included inflammation. The microbiota is known to interact with brain and can promote inflammation. The objective of this study is to describe microbiota with taxonomic and metabolomic analysis. A comparison between ruptured and unruptured intracranial aneurysm will be performed. The study hypothesis is that microbiota is different between ruptured and unruptured patient.

03

Conditions studied

  • Intracranial Sacciform Aneurysm

Keywords

  • Intracranial aneurysm
  • intestinal microbiota
  • risk factor
  • ruptured
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

adult patients with ruptured aneurysm and unruptured aneurysm

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • one or more intracranial sacciform aneurysm ruptured or not in function of the inclusion group

Exclusion criteria

Exclusion Criteria:

  • Transient modification of microbiota: Antibiotherapy in the last 3 months, pre or probiotic in the last month, gastrostomy, ileostomy, bariatric surgery, digestive tract resection, gastro-duodenal ulcer surgery or during the last month, chronic inflammatory disease of the digestive tract (like Crohn), for more than 30, Very restrictive diet (like vegan
  • Specific pathologies increasing the incidence of aneurysm ( kidney autosomic dominant polycystosis, Type 1 neurofibromatosis, Rendu-Osler, MArfan
  • Participation to a study with the objective of microbiota modification
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Ruptured

    Patient with a ruptured intracranial sacciform aneurysm for all location. The diagnosis of ruptured aneurysm is made on MRI, Angio-CT or digital substraction angiography with no doubt

    Biological: analysis of foecal microbiota

  • unruptured

    Patient with an unruptured intracranial sacciform aneurysm for all location. The diagnosis of unuptured aneurysm is made on MRI, Angio-CT or digital substraction angiography with no doubt

    Biological: analysis of foecal microbiota

Interventions

  • Biologicalanalysis of foecal microbiota

    An analysis of foecal microbiota including taxonomic and metabolomic analysis will be performed and compared between ruptured and unruptured patient. confundens factors as diet, obesity for microbiota and as smoking, hypertension, size for aneurysm ruptured will be sampled and independence will be analyzed.

06

What researchers measure

Primary outcomes

  1. Taxonomic faecal microbiota description

    The results of the taxonomic analysis of fecal samples will be described in the two groups. Interesting parameter will be selected for further analysis

    Time frame: The faecal samples will be taken at 3 days+/-2 after the ruptured and during the arteriography for the unruptured group within 3 months after inclusion

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jun 2029, 51 months after the start.

Of 68 non-industry observational studies under Intracranial Aneurysm, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 145. This study's planned 51 months is close to that.

Counting every sponsor, half of 105 studies reached it within 46 months; a quarter within 36 and three quarters within 145.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: start Aug 2024 → Mar 2025, primary completion Aug 2026 → Jun 2029 and completion Aug 2026 → Jun 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2023
First posted
Jun 22, 2023
StartActual
Mar 28, 2025was Aug 2024
Primary completionEst.
Jun 28, 2029was Aug 2026
CompletionEst.
Jun 28, 2029was Aug 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 2, 2026
Sites
1 site added — first site in France
Show site
  • Hôpital neurologique Pierre Wertheimer · Bron, France
Nov 2, 2026
Start date
Aug 31, 2024→Mar 28, 2025 (actual)
Nov 2, 2026
Primary completion
Aug 31, 2026→Jun 28, 2029
Nov 2, 2026
Study completion
Aug 31, 2026→Jun 28, 2029
Nov 2, 2026
Contact
Study contact changed: •••5839→•••7844; added j•••@chu-lyon.fr · •••6301. See the current contact
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in France
    Show site
    • Hôpital neurologique Pierre Wertheimer · Bron, France
    Start date Aug 31, 2024→Mar 28, 2025 (now actual)
    Primary completion Aug 31, 2026→Jun 28, 2029
    Study completion Aug 31, 2026→Jun 28, 2029
    Contact Study contact changed: •••5839→•••7844; added j•••@chu-lyon.fr · •••6301. See the current contact
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05914636
Responsible party
Sponsor
First posted
Jun 22, 2023
Start date
Mar 28, 2025
Primary completion
Jun 28, 2029 (estimated)
Completion
Jun 28, 2029 (estimated)
Last update
Nov 2, 2026

Study contacts

Dumot Chloé, Dr PhD
Contact
chloe.dumot@chu-lyon.fr
+33 4 72 35 78 44
Julien BERTHILLER
Contact
julien.berthiller@chu-lyon.fr
+33 4 27 85 63 01
Dumot Chloé, Dr PhD
principal investigator · Hôpital neurologique P. Wertheimer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion